A method of treating a patient with breast cancer includes administering
to the patient a breast cancer cell proliferation-inhibiting amount
of a methylol-containing compound such as taurolidine, taurultam
or a mixture thereof.
Microarrays specific for breast cancer are provided. Also provided
are methods for detecting breast cancer in patients or screening
therapeutics for the treatment or prevention of breast cancer by
analyzing expression levels of specific genes in BECs or quantifying
specific protein levels in breast ductal fluid.
The invention provides a variety of reagents for use in the diagnosis
and management of breast cancer. The invention utilizes cDNA microarray
technology to identify genes whose expression profile across a large
group of tumor samples correlates with that of cytokeratin 5 and
cytokeratin 17, markers for basal cells of the normal mammary lactation
gland. The invention demonstrates that tumors that express cytokeratin
5/6 and/or 17 have a poor prognosis relative to tumors overall.
The invention provides basal marker genes and their expression products
and uses of these genes for diagnosis of breast cancer and for identification
of therapies for breast cancer. In particular, the invention provides
basal marker genes including cadherin3, matrix metalloproteinase
14, and cadherin EGF LAG seven-pass G-type receptor 2. The invention
provides antibodies to the polypeptides expressed by these genes
and methods of use thereof.
Systematic comparisons of breast ductal fluid samples obtained
by nipple aspiration from women with unilateral breast cancer revealed
significant differences in ductal fluid protein expression between
the breast with cancer and the breast without cancer in each patient.
This study demonstrates that breast ductal fluid contains over 1000
separate protein species and suggests that ductal fluids from breast
cancer patients may be useful for high-throughput biomarker discovery.